INF + Dietary Education for Diabetic Neuropathy
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether adding dietary education to a physical therapy technique called Intraneural Facilitation® Therapy (INF® Therapy) can improve symptoms of diabetic nerve pain. INF® Therapy aims to boost blood flow to nerves, potentially easing discomfort from distal symmetric polyneuropathy, a common type of diabetic nerve damage. The trial includes two groups: one receiving only INF® Therapy and another receiving INF® Therapy with guidance on a gluten-free diet. Ideal participants are adults with type II diabetes who experience moderate to severe nerve pain below the knees and can move independently without assistive devices. As an unphased trial, this study offers a unique opportunity to explore innovative approaches to managing diabetic nerve pain.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you have any chronic medical conditions requiring active treatment, you may not be eligible to participate.
What prior data suggests that Intraneural Facilitation® Therapy (INF® Therapy) is safe for treating distal symmetric polyneuropathy (DSPN)?
Research shows that Intraneural Facilitation® Therapy (INF® Therapy) is a hands-on treatment designed to improve blood flow in nerves. However, specific safety information for this therapy is not yet available. Since the trial is in its early stages, safety data for humans remains limited.
Additionally, no specific safety information exists for using INF® Therapy alongside dietary education. The dietary component includes gluten-free meal ideas, which are generally safe for most people. The absence of safety data means tolerance levels for INF® Therapy are unknown. Potential participants should consider this and consult their doctor if they have any concerns.12345Why are researchers excited about this trial?
Unlike the standard treatments for diabetic neuropathy, which often involve medications like pain relievers or antidepressants to manage symptoms, the Intraneural Facilitation® Therapy (INF® Therapy) focuses on improving blood flow directly to the nerves. This manual therapy technique uses a series of specific pressure holds to enhance circulation in and around nerve tissues, potentially offering a more targeted approach to alleviate nerve pain. Additionally, when combined with dietary education that emphasizes a gluten-free diet, this treatment could provide a more holistic approach by addressing potential dietary contributors to nerve inflammation. Researchers are excited because this therapy could offer a non-drug alternative that directly targets the underlying issues in diabetic neuropathy rather than just masking the symptoms.
What evidence suggests that this trial's treatments could be effective for diabetic neuropathy?
Research shows that Intraneural Facilitation (INF) Therapy, one of the treatments in this trial, may help treat diabetic peripheral neuropathy. Studies have found that INF treatment can reduce pain, improve balance, and enhance protective sensations in patients by increasing blood flow to the nerves, potentially relieving symptoms.
In this trial, some participants will receive INF Therapy combined with dietary education, particularly a gluten-free diet, which might enhance these benefits. Early findings suggest that this combination can further improve pain relief and quality of life. Overall, evidence supports that both INF Therapy alone and with dietary education could effectively manage neuropathy symptoms.12367Who Is on the Research Team?
Eric G Johnson, DSc, MS-HPEd
Principal Investigator
Department of Physical Therapy School of Allied Health Professions, Loma Linda University
Are You a Good Fit for This Trial?
This trial is for adults aged 50-75 with Type II diabetes and moderate to severe diabetic peripheral neuropathy (DPN), specifically the distal symmetric polyneuropathy (DSPN) type. Participants should be able to perform daily activities without walking aids. Excluded are pregnant individuals, those with certain medical conditions or dietary restrictions, metal allergies, or undergoing specific treatments like chemotherapy.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Initial Assessment
Participants complete informed consent, VAS pain scale, HIPAA, and medical screening documents. Randomization into groups occurs.
Treatment
Participants receive INF® Therapy for ten sessions, two sessions per week. The INF® Therapy+ group also receives dietary education.
Immediate Post-Intervention Assessment
Participants undergo post-intervention measurements immediately after completing the ten INF® Therapy sessions.
Follow-up
Participants are monitored for changes in neuropathy severity, balance stability, pain intensity, and other outcomes three months post-INF® Therapy.
What Are the Treatments Tested in This Trial?
Interventions
- Dietary Education
- Intraneural Facilitation (INF)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Loma Linda University
Lead Sponsor